Bayer Zydus Pharma operates in key segments of the Indian pharmaceuticals market with a strong and successful product list.
This area provides access to press releases and media interaction.
The Pharmaceuticals Division focuses on prescription products, especially for women’s healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises of the Diagnostic Imaging business which markets contrast agents.
With our innovative products, we seek to achieve a significant therapeutic benefit for patients, while at the same time satisfying the growing requirements of physicians.
On a global level, in the medium term, our recently launched products such as Xarelto™, Eylea™, Stivarga™, Xofigo™ and Adempas™ in particular should contribute to increased sales. To safeguard our growth in the long term, we will be further expanding our early-stage research activities and driving forward the clinical development of active ingredient candidates discovered in-house. Moreover, we will continue to systematically supplement our development portfolio by means of licensing agreements and acquisitions.
In India, the Pharmaceuticals Division markets products under the joint venture company Bayer Zydus Pharma.
Products from Bayer Zydus Pharma